国内首款分化型甲状腺癌术后评估新药获批

新京报01-09

新京报讯（记者张兆慧）1月8日，国家药监局官网显示，苏州泽璟生物制药股份有限公司（简称“泽璟制药”）自主研发的注射用重组人促甲状腺激素产品泽速宁（通用名：注射用人促甲状腺素β）获批上市。该药用于分化型甲状腺癌（DTC）患者在甲状腺全切或近全切除术后随访中的协同诊断，以进行血清甲状腺球蛋白（Tg）检测，伴或不伴放射性碘（¹³¹I）全身显像（WBS）检查，是国内首个用于分化型甲状腺癌术后评估的新药。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602637858?lang=zh_CN&edition=full","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl882026191910472863921.JPG?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","is_english":false,"pubTime":"2026-01-09 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602637858","market":"hk","top_or_hot":-1,"title":"国内首款分化型甲状腺癌术后评估新药获批","media":"新京报","content":"<div>\n<p>新京报讯（记者张兆慧）1月8日，国家药监局官网显示，苏州泽璟生物制药股份有限公司（简称“泽璟制药”）自主研发的注射用重组人促甲状腺激素产品泽速宁（通用名：注射用人促甲状腺素β）获批上市。该药用于分化型甲状腺癌（DTC）患者在甲状腺全切或近全切除术后随访中的协同诊断，以进行血清甲状腺球蛋白（Tg）检测，伴或不伴放射性碘（¹³¹I）全身显像（WBS）检查，是国内首个用于分化型甲状腺癌术后评估的新药。...</p>\n\n<a href=\"https://www.bjnews.com.cn/detail/1767959277169358.html\">网页链接</a>\n\n</div>\n","source":"highlight_bjnews","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国内首款分化型甲状腺癌术后评估新药获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国内首款分化型甲状腺癌术后评估新药获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 19:47 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.bjnews.com.cn/detail/1767959277169358.html><strong>新京报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新京报讯（记者张兆慧）1月8日，国家药监局官网显示，苏州泽璟生物制药股份有限公司（简称“泽璟制药”）自主研发的注射用重组人促甲状腺激素产品泽速宁（通用名：注射用人促甲状腺素β）获批上市。该药用于分化型甲状腺癌（DTC）患者在甲状腺全切或近全切除术后随访中的协同诊断，以进行血清甲状腺球蛋白（Tg）检测，伴或不伴放射性碘（¹³¹I）全身显像（WBS）检查，是国内首个用于分化型甲状腺癌术后评估的新药。...</p>\n\n<a href=\"https://www.bjnews.com.cn/detail/1767959277169358.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.bjnews.com.cn/detail/1767959277169358.html","article_id":"2602637858","we_media_id":null,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl882026191910472863921.JPG?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767959277169358.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602637858","pubTimestamp":1767959220,"columns":[],"sourceInfo":{"source_id":"highlight_bjnews","name":"新京报"},"weMediaInfo":null,"summary":"目前我国甲状腺癌发病率已位居癌症发病率第三位，尽管患者5年生存率已提升至92.9%，但术后10年复发率仍可达20%。其中术后动态疗效评估是制定个体化治疗方案和随访策略的关键。加之部分患者术后随访规范性不足，制约了甲状腺癌患者术后管理个体化。","collect":0,"end_time":0,"defaultTopTitle":"bjnews.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4211":"区域性银行","WBS":"韦伯斯特金融"},"translate_title":"China's first new drug for postoperative evaluation of differentiated thyroid cancer was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WBS":1},"content_text":"新京报讯（记者张兆慧）1月8日，国家药监局官网显示，苏州泽璟生物制药股份有限公司（简称“泽璟制药”）自主研发的注射用重组人促甲状腺激素产品泽速宁（通用名：注射用人促甲状腺素β）获批上市。该药用于分化型甲状腺癌（DTC）患者在甲状腺全切或近全切除术后随访中的协同诊断，以进行血清甲状腺球蛋白（Tg）检测，伴或不伴放射性碘（¹³¹I）全身显像（WBS）检查，是国内首个用于分化型甲状腺癌术后评估的新药。目前我国甲状腺癌发病率已位居癌症发病率第三位，尽管患者5年生存率已提升至92.9%，但术后10年复发率仍可达20%。其中术后动态疗效评估是制定个体化治疗方案和随访策略的关键。但传统停用甲状腺激素类药物（简称“停药法”）常导致患者出现甲减症状、情绪波动，严重影响其生活质量。加之部分患者术后随访规范性不足，制约了甲状腺癌患者术后管理个体化。去年6月，默克与泽璟制药达成合作协议，默克获得泽速宁在中国大陆地区的独家商业化权益。“长期以来，DTC术后管理始终缺乏一种快速、精准的动态评估方法，这不仅导致术后实时疾病状态评估的不足，影响后续诊疗的精准制定，也可能影响患者的预后。”北京协和医院核医学科林岩松教授指出，泽速宁获批上市，意味着广大患者不再受限于传统方法，能够真正实现个体化、精准化的术后管理。校对 穆祥桐","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602637858","isCrawlerRequest":true}